Principal Investigators

    Dr R Killick


    King's College London

    Contact information of lead PI


    United Kingdom

    Title of project or programme

    Pathway-driven identification of therapeutic targets for combatting Alzheimer's disease.

    Source of funding information


    Total sum awarded (Euro)

    € 1,357,029

    Start date of award


    Total duration of award in years


    The project/programme is most relevant to:

    Alzheimer's disease & other dementias


    Research Abstract

    Our aim is to gain a better understanding of the signaling mechanisms driving beta-amyloid neurotoxicity, to identify effective and tractable novel therapeutic targets in the pathway and to develop assays suitable for future high throughput screening ready to identify small molecules acting on them. We are in a unique position to do this following our discoveries concerning the pathway activated by beta-amyloid, which mediates its neurotoxic properties including; tau phosphorylation, neuronal death, synaptotoxicity and, in vivo, cognitive impairment. This pathway, the wnt-Planar Cell Polarity (wnt-PCP) pathway, is also detectable in the Alzheimer’s disease (AD) brain. Of major significance for our understanding of AD pathology, the beta-amyloid precursor protein (APP), from which beta-amyloid is derived, has been identified as a necessary component of the wnt-PCP pathway where it is needed to drive it through recruitment of Abl: Thus, the beta-amyloid induction of wnt-PCP signaling is APP-dependent! Our understanding of the pathway will now enable us to decipher it further and more fully define the roles of APP and beta-amyloid within it. We will employ a range of techniques in cell lines and neurons, and validate findings in tissues from animal models and man. In the process we will identify novel, apt therapeutic targets through which to target the disease. Our adoption of peptide array technology to rapidly and accurately map specific protein-protein interactions, will not only help pathway elucidation but will also generate binding peptides, with which, and their binding partner proteins, we will generate assay suitable for future high throughput screening. Thus at the end of this project we will be in good position to commence small molecule identification with a battery of neuron based assays in place ready to evaluate active compounds. Such undertakings will, of course, be dependent on our obtaining further funding.

    Lay Summary

    Further information available at:

Types: Investments > €500k
Member States: United Kingdom
Diseases: Alzheimer's disease & other dementias
Years: 2016
Database Categories: N/A
Database Tags: N/A

Export as PDF